<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795275</url>
  </required_header>
  <id_info>
    <org_study_id>07-0749</org_study_id>
    <nct_id>NCT00795275</nct_id>
  </id_info>
  <brief_title>Incretin Effect in People With Impaired Fasting Glucose</brief_title>
  <acronym>1651</acronym>
  <official_title>Exploring the Incretin Effect in People With IFG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of&#xD;
      glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to&#xD;
      abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the&#xD;
      objective of the current study. The investigators hypothesized that defects in GLP-1 may&#xD;
      explain the inappropriate basal EGP and diminished insulin secretion in IFG, and,&#xD;
      furthermore, that by increasing circulating GLP-1 levels (using a new medicine called&#xD;
      &quot;sitagliptin&quot;) the investigators could reverse these defects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endogenous Glucose Production</measure>
    <time_frame>Baseline and 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Insulin Secretion</measure>
    <time_frame>Baseline and 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Secretion in Response to Oral vs. IV Glucose</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change in Hormones, Substrates and Insulin Action: C-peptide</measure>
    <time_frame>Baseline and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change in Hormones, Substrates and Insulin Action: Glucagon</measure>
    <time_frame>Baseline and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change in Hormones, Substrates and Insulin Action: GLP-1</measure>
    <time_frame>Baseline and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change in Hormones, Substrates and Insulin Action: Lactate</measure>
    <time_frame>Baseline and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change in Hormones, Substrates and Insulin Action: FFA</measure>
    <time_frame>Baseline and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change in Hormones, Substrates and Insulin Action: Glycerol</measure>
    <time_frame>Baseline and 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Impaired Fasting Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal glucose tolerance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin Phosphate</intervention_name>
    <description>Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
    <arm_group_label>Impaired Fasting Glucose</arm_group_label>
    <arm_group_label>Normal glucose tolerance</arm_group_label>
    <other_name>brand name: Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, sedentary, non-smokers, men and women 45-70 years old Subjects were placed&#xD;
             into 1 of the 2 groups based on two 2-hour 75g oral glucose tolerance tests (2h OGTT),&#xD;
             separated by one week: a control group with normal glucose tolerance (NGT; n=14;&#xD;
             fasting glucose &lt;5.6 mmol/l and 2h OGTT &lt;7.8 mmol/l), or IFG (n=10; fasting glucose&#xD;
             5.6-6.9 mmol/l, and 2h OGTT &lt;7.8 mmol/l).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects were excluded for: thyroid stimulating hormone &lt;50 or &gt;500 milliunits/L,&#xD;
             fasting triglycerides &gt;10.3 mmol/l, creatinine &gt;130 Î¼mol/l, elevated liver function&#xD;
             tests (&gt;2 times normal), hematocrit &lt; 38%, or white blood cell count &lt;3.0 x 103. Use&#xD;
             of medications for lipid and/or glucose lowering also excluded enrollees. Women may&#xD;
             not have used hormone replacement therapy in the past 1 year. Smokers. BMI &lt;25 or &gt;40&#xD;
             kg/m2. Diabetes or impaired glucose tolerance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leigh Perreault, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>January 23, 2013</results_first_submitted>
  <results_first_submitted_qc>March 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2021</results_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-diabetes</keyword>
  <keyword>isotopes</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>insulin action</keyword>
  <keyword>GLP-1</keyword>
  <keyword>simple obesity</keyword>
  <keyword>impaired fasting glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>People With Impaired Fasting Glucose</title>
          <description>people with impaired fasting glucose&#xD;
Januvia (sitagliptin phosphate) : Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
        </group>
        <group group_id="P2">
          <title>People With Normal Glucose Tolerance</title>
          <description>people with normal glucose tolerance&#xD;
Januvia (sitagliptin phosphate) : Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>People With Impaired Fasting Glucose</title>
          <description>people with impaired fasting glucose&#xD;
Januvia (sitagliptin phosphate) : Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
        </group>
        <group group_id="B2">
          <title>People With Normal Glucose Tolerance</title>
          <description>people with normal glucose tolerance&#xD;
Januvia (sitagliptin phosphate) : Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="2.3"/>
                    <measurement group_id="B2" value="58" spread="1.6"/>
                    <measurement group_id="B3" value="59" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Endogenous Glucose Production</title>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>People With Impaired Fasting Glucose</title>
            <description>people with impaired fasting glucose&#xD;
Januvia (sitagliptin phosphate) : Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>People With Normal Glucose Tolerance</title>
            <description>people with normal glucose tolerance&#xD;
Januvia (sitagliptin phosphate) : Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endogenous Glucose Production</title>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.08"/>
                    <measurement group_id="O2" value="1.46" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.04"/>
                    <measurement group_id="O2" value="1.37" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Secretion</title>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Impaired Fasting Glucose</title>
            <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>Normal Glucose Tolerance</title>
            <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Secretion</title>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" spread="15"/>
                    <measurement group_id="O2" value="97" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="8"/>
                    <measurement group_id="O2" value="71" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Secretion in Response to Oral vs. IV Glucose</title>
        <time_frame>Baseline</time_frame>
        <population>Despite significant efforts to recover the data, data for this outcome measure could not be obtained and is not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Impaired Fasting Glucose</title>
            <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>Normal Glucose Tolerance</title>
            <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion in Response to Oral vs. IV Glucose</title>
          <population>Despite significant efforts to recover the data, data for this outcome measure could not be obtained and is not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change in Hormones, Substrates and Insulin Action: C-peptide</title>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Impaired Fasting Glucose</title>
            <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>Normal Glucose Tolerance</title>
            <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Change in Hormones, Substrates and Insulin Action: C-peptide</title>
          <units>nmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.05"/>
                    <measurement group_id="O2" value="0.7" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.03"/>
                    <measurement group_id="O2" value="0.7" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change in Hormones, Substrates and Insulin Action: Glucagon</title>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Impaired Fasting Glucose</title>
            <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>Normal Glucose Tolerance</title>
            <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Change in Hormones, Substrates and Insulin Action: Glucagon</title>
          <units>ng/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" spread="2.8"/>
                    <measurement group_id="O2" value="63" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="3.1"/>
                    <measurement group_id="O2" value="66" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change in Hormones, Substrates and Insulin Action: GLP-1</title>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Impaired Fasting Glucose</title>
            <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>Normal Glucose Tolerance</title>
            <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Change in Hormones, Substrates and Insulin Action: GLP-1</title>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="3.6"/>
                    <measurement group_id="O2" value="3.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="2.6"/>
                    <measurement group_id="O2" value="5.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change in Hormones, Substrates and Insulin Action: Lactate</title>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Impaired Fasting Glucose</title>
            <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>Normal Glucose Tolerance</title>
            <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Change in Hormones, Substrates and Insulin Action: Lactate</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.03"/>
                    <measurement group_id="O2" value="0.3" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.09"/>
                    <measurement group_id="O2" value="0.4" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change in Hormones, Substrates and Insulin Action: FFA</title>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Impaired Fasting Glucose</title>
            <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>Normal Glucose Tolerance</title>
            <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Change in Hormones, Substrates and Insulin Action: FFA</title>
          <units>umol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604" spread="30"/>
                    <measurement group_id="O2" value="610" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="631" spread="51"/>
                    <measurement group_id="O2" value="547" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change in Hormones, Substrates and Insulin Action: Glycerol</title>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Impaired Fasting Glucose</title>
            <description>Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
          <group group_id="O2">
            <title>Normal Glucose Tolerance</title>
            <description>Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)&#xD;
Sitagliptin Phosphate: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Change in Hormones, Substrates and Insulin Action: Glycerol</title>
          <units>umol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="6"/>
                    <measurement group_id="O2" value="85" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="6.5"/>
                    <measurement group_id="O2" value="85" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>People With Impaired Fasting Glucose</title>
          <description>people with impaired fasting glucose&#xD;
Januvia (sitagliptin phosphate) : Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
        </group>
        <group group_id="E2">
          <title>People With Normal Glucose Tolerance</title>
          <description>people with normal glucose tolerance&#xD;
Januvia (sitagliptin phosphate) : Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leigh Perreault, MD</name_or_title>
      <organization>University of Colorado Anschutz Medical Campus</organization>
      <phone>303-249-7732</phone>
      <email>leigh.perreault@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

